- Report
- March 2024
- 195 Pages
Global
From €3242EUR$3,374USD£2,783GBP
€3602EUR$3,749USD£3,092GBP
- Report
- March 2024
- 196 Pages
Global
From €3242EUR$3,374USD£2,783GBP
€3602EUR$3,749USD£3,092GBP
- Report
- March 2024
- 185 Pages
Global
From €3242EUR$3,374USD£2,783GBP
€3602EUR$3,749USD£3,092GBP
- Report
- March 2024
- 188 Pages
Global
From €3242EUR$3,374USD£2,783GBP
€3602EUR$3,749USD£3,092GBP
- Report
- March 2024
- 196 Pages
Global
From €3242EUR$3,374USD£2,783GBP
€3602EUR$3,749USD£3,092GBP
- Report
- March 2024
- 194 Pages
Global
From €3242EUR$3,374USD£2,783GBP
€3602EUR$3,749USD£3,092GBP
- Report
- January 2024
- 348 Pages
Global
From €5245EUR$5,649USD£4,350GBP
- Report
- July 2023
- 74 Pages
Global
From €5717EUR$5,950USD£4,908GBP
- Report
- April 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- March 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- January 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- January 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- May 2024
- 507 Pages
Global
From €5381EUR$5,600USD£4,619GBP
- Report
- May 2024
- 620 Pages
Global
From €5381EUR$5,600USD£4,619GBP
- Report
- May 2024
- 194 Pages
Global
From €4756EUR$4,950USD£4,083GBP
- Report
- April 2024
- 137 Pages
Global
From €3746EUR$3,899USD£3,216GBP
- Report
- March 2024
- 143 Pages
Global
From €3746EUR$3,899USD£3,216GBP
- Report
- November 2023
- 145 Pages
Global
From €2401EUR$2,499USD£2,061GBP
- Report
- July 2023
- 141 Pages
Global
From €2401EUR$2,499USD£2,061GBP
The Dry Powder Inhaler (DPI) market is a segment of the respiratory drugs market. It is a device used to deliver medication to the lungs in the form of a dry powder. It is a convenient and efficient way to deliver medication to the lungs, as it does not require the use of a propellant gas. DPIs are used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver vaccines and other medications.
DPIs are becoming increasingly popular due to their convenience and effectiveness. They are also cost-effective, as they require fewer components than other inhalers. Additionally, DPIs are easy to use and can be used by patients of all ages.
Several companies are involved in the DPI market, including GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of DPIs. Show Less Read more